PPFIBP2

Summary

PPFIBP2 (PPFIB scaffold protein 2, HGNC:9250) is a protein-coding gene on chromosome 11p15.4, encoding Liprin-beta-2 (Q8ND30). May regulate the disassembly of focal adhesions.

This gene encodes a member of the LAR protein-tyrosine phosphatase-interacting protein (liprin) family. The encoded protein is a beta liprin and plays a role in axon guidance and neuronal synapse development by recruiting LAR protein-tyrosine phosphatases to the plasma membrane. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 8495 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 172 total
• MANE Select transcript: NM_003621

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9250
Approved symbol	PPFIBP2
Name	PPFIB scaffold protein 2
Location	11p15.4
Locus type	gene with protein product
Status	Approved
Aliases	Cclp1
Ensembl gene	ENSG00000166387
Ensembl biotype	protein_coding
OMIM	603142
Entrez	8495

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 21 protein_coding, 8 retained_intron, 4 protein_coding_CDS_not_defined

ENST00000299492, ENST00000524495, ENST00000524548, ENST00000525597, ENST00000526046, ENST00000526873, ENST00000527790, ENST00000528883, ENST00000528929, ENST00000528947, ENST00000529021, ENST00000529321, ENST00000529575, ENST00000529664, ENST00000530081, ENST00000530181, ENST00000530189, ENST00000530582, ENST00000532112, ENST00000532172, ENST00000532381, ENST00000532416, ENST00000532926, ENST00000533792, ENST00000534409, ENST00000534552, ENST00000650027, ENST00000684123, ENST00000684215, ENST00000857460, ENST00000857461, ENST00000857462, ENST00000933098

RefSeq mRNA: 13 — MANE Select: NM_003621 NM_001256568, NM_001256569, NM_001351853, NM_001351854, NM_001351855, NM_001351856, NM_001351857, NM_001351858, NM_001351859, NM_001351860, NM_001351861, NM_001351862, NM_003621

CCDS: CCDS31419, CCDS58116, CCDS58117, CCDS91429

Canonical transcript exons

ENST00000299492 — 24 exons

Exon	Start	End
ENSE00001102530	7630925	7631028
ENSE00001102532	7620935	7621027
ENSE00001102550	7625777	7625891
ENSE00001102612	7565553	7565767
ENSE00001278528	7549440	7549539
ENSE00001416579	7513999	7514121
ENSE00002165121	7653024	7653756
ENSE00003459098	7648800	7648911
ENSE00003461718	7649147	7649235
ENSE00003486919	7597560	7597673
ENSE00003494124	7651656	7651844
ENSE00003495430	7610291	7610422
ENSE00003508660	7642298	7642426
ENSE00003522623	7648387	7648537
ENSE00003523268	7593132	7593224
ENSE00003525289	7628285	7628346
ENSE00003531317	7650840	7650965
ENSE00003548904	7639732	7639870
ENSE00003554286	7634495	7634552
ENSE00003558134	7649532	7649654
ENSE00003590234	7635552	7635593
ENSE00003608843	7641479	7641620
ENSE00003630802	7629459	7629534
ENSE00003687177	7632867	7632934

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 97.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.8198 / max 119.5701, expressed in 1349 samples.

FANTOM5 promoters (22 alternative TSS)

Promoter ID	TPM avg	Samples expressed
112903	2.2540	712
112902	1.4594	665
112914	0.4449	254
112901	0.3498	195
112913	0.2779	151
112912	0.2687	106
112922	0.2678	85
112926	0.2075	75
112907	0.1994	90
112924	0.1932	58

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	97.93	gold quality
sural nerve	UBERON:0015488	97.46	gold quality
hair follicle	UBERON:0002073	96.89	gold quality
skin of leg	UBERON:0001511	95.64	gold quality
skin of abdomen	UBERON:0001416	95.55	gold quality
saliva-secreting gland	UBERON:0001044	95.47	gold quality
right uterine tube	UBERON:0001302	95.47	gold quality
calcaneal tendon	UBERON:0003701	95.38	gold quality
minor salivary gland	UBERON:0001830	95.15	gold quality
lower esophagus mucosa	UBERON:0035834	94.70	gold quality
right lobe of thyroid gland	UBERON:0001119	94.64	gold quality
thyroid gland	UBERON:0002046	94.61	gold quality
left lobe of thyroid gland	UBERON:0001120	94.55	gold quality
zone of skin	UBERON:0000014	94.46	gold quality
right lobe of liver	UBERON:0001114	94.44	gold quality
mucosa of transverse colon	UBERON:0004991	94.38	gold quality
left testis	UBERON:0004533	94.27	gold quality
mouth mucosa	UBERON:0003729	94.06	gold quality
right testis	UBERON:0004534	94.05	gold quality
rectum	UBERON:0001052	93.98	gold quality
seminal vesicle	UBERON:0000998	93.66	gold quality
esophagus mucosa	UBERON:0002469	92.82	gold quality
testis	UBERON:0000473	92.78	gold quality
stomach	UBERON:0000945	92.52	gold quality
body of stomach	UBERON:0001161	92.52	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.27	gold quality
metanephros cortex	UBERON:0010533	92.25	gold quality
nerve	UBERON:0001021	91.99	gold quality
tibial nerve	UBERON:0001323	91.99	gold quality
tonsil	UBERON:0002372	91.85	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-109979	yes	296.67
E-HCAD-10	yes	14.65
E-MTAB-9388	yes	13.35
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

10 targeting PPFIBP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-5582-5P	99.27	71.42	1879
HSA-MIR-4711-3P	98.97	66.87	1020
HSA-MIR-6823-5P	96.26	65.69	919

Literature-anchored findings (GeneRIF, showing 5)

• analysis of crystal structure of the central coiled-coil domain from human liprin-beta2 (PMID:21462929)
• Knockdown of either Rab17 or liprin-beta2 restores invasiveness of ERK2-depleted cells, indicating that ERK2 drives invasion of MDA-MB-231 cells by suppressing expression of these genes. (PMID:22328529)
• rs12791447 is associated with prostate cancer susceptibility in Asians. mRNA levels of PPFIBP2 are differentially expressed in prostate tumours and paired normal tissues. (PMID:26443449)
• Analysis of the role of liprin-beta1 and liprin-beta2 has shown that while liprin-beta1 contributes positively to tumour cell motility in vitro; liprin-beta2 has a negative effect on both cell motility and invasion. (PMID:26663347)
• germline mutations in a novel gene, PPFIBP2, differentiated risk for lethal prostate cancer from low-risk cases and were associated with shorter survival times after diagnosis. (PMID:30043417)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppfibp2b	ENSDARG00000029168
danio_rerio	ppfibp2a	ENSDARG00000061977
mus_musculus	Ppfibp2	ENSMUSG00000036528
rattus_norvegicus	Ppfibp2	ENSRNOG00000019667
drosophila_melanogaster	Liprin-beta	FBGN0036376
caenorhabditis_elegans		WBGENE00011904

Paralogs (5): PPFIBP1 (ENSG00000110841), PPFIA1 (ENSG00000131626), PPFIA2 (ENSG00000139220), PPFIA4 (ENSG00000143847), PPFIA3 (ENSG00000177380)

Protein

Protein identifiers

Liprin-beta-2 — Q8ND30 (reviewed: Q8ND30)

Alternative names: Protein tyrosine phosphatase receptor type f polypeptide-interacting protein-binding protein 2

All UniProt accessions (14): A0A3B3IS15, A0A804HJY3, A0A804HKA2, Q8ND30, E9PI79, E9PIK8, E9PJA0, E9PK17, E9PMH3, E9PMN3, E9PP16, H0YDJ2, H0YDM0, H0YET1

UniProt curated annotations — full annotation on UniProt →

Function. May regulate the disassembly of focal adhesions. Did not bind receptor-like tyrosine phosphatases type 2A.

Subunit / interactions. Forms homodimers and heterodimers.

Tissue specificity. Widely expressed.

Domain organisation. The N-terminal coiled coil regions mediate homodimerization preferentially and heterodimerization type beta/beta. The C-terminal, non-coiled coil regions mediate heterodimerization type beta/alpha.

Similarity. Belongs to the liprin family. Liprin-beta subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8ND30-1	1	yes
Q8ND30-2	2
Q8ND30-3	3

RefSeq proteins (13): NP_001243497, NP_001243498, NP_001338782, NP_001338783, NP_001338784, NP_001338785, NP_001338786, NP_001338787, NP_001338788, NP_001338789, NP_001338790, NP_001338791, NP_003612* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001660	SAM	Domain
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR029515	Liprin	Family
IPR037617	LIPB1/2_SAM_1	Domain
IPR037618	LIPB1/2_SAM_2nd	Domain
IPR037619	LIPB1/2_SAM_3rd	Domain
IPR058914	LIPB1/2_CC	Domain

Pfam: PF00536, PF07647, PF26022

UniProt features (25 total): sequence conflict 5, modified residue 4, splice variant 4, region of interest 4, domain 3, chain 1, sequence variant 1, helix 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3QH9	X-RAY DIFFRACTION	2.01

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8ND30-F1	71.04	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 329, 363, 387, 512

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-388844	Receptor-type tyrosine-protein phosphatases
R-HSA-112316	Neuronal System
R-HSA-6794362	Protein-protein interactions at synapses

MSigDB gene sets: 180 (showing top): GOBP_NEUROMUSCULAR_JUNCTION_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, CERVERA_SDHB_TARGETS_1_DN, GOBP_CELL_JUNCTION_ORGANIZATION, BLALOCK_ALZHEIMERS_DISEASE_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, GOCC_SYNAPSE, MASSARWEH_TAMOXIFEN_RESISTANCE_UP, GOCC_PRESYNAPTIC_ACTIVE_ZONE, GOCC_PRESYNAPSE, ZHENG_GLIOBLASTOMA_PLASTICITY_DN

GO Biological Process (1): neuromuscular junction development (GO:0007528)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), cytosol (GO:0005829), presynaptic active zone (GO:0048786), presynapse (GO:0098793)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Protein-protein interactions at synapses	1
Neuronal System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
synapse organization	1
protein binding	1
binding	1
cytoplasm	1
presynapse	1
synapse	1

Protein interactions and networks

STRING

532 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPFIBP2	PTPRS	Q13332	683
PPFIBP2	PTPRD	P23468	642
PPFIBP2	TCFL5	Q9UL49	574
PPFIBP2	GRIP1	Q9Y3R0	570
PPFIBP2	TRIO	O75962	480
PPFIBP2	PPFIA1	Q13136	477
PPFIBP2	GLOD5	A6NK44	472
PPFIBP2	GRIA1	P42261	470
PPFIBP2	PPFIA3	O75145	466
PPFIBP2	PPFIA2	O75334	446
PPFIBP2	PPFIA4	O75335	437
PPFIBP2	PTPRF	P10586	430
PPFIBP2	MRRF	Q96E11	424
PPFIBP2	TMEM231	Q9H6L2	418
PPFIBP2	TIFAB	Q6ZNK6	418

IntAct

33 interactions, top by confidence:

A	B	Type	Score
CRK	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.800
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
PPFIBP2	RPC11	psi-mi:“MI:0915”(physical association)	0.560
RPC11	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.560
PPFIBP2	HSF4	psi-mi:“MI:0915”(physical association)	0.560
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
CRK	ARHGAP42	psi-mi:“MI:0914”(association)	0.530
PPFIBP2	SNAP29	psi-mi:“MI:0914”(association)	0.530
PPFIBP2	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
PPFIBP2	SFN	psi-mi:“MI:0915”(physical association)	0.400
CRKL	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.370
TSG101	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.370
DTNB	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.370
GAMMAHV.ORF23	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.370
YWHAG	C1orf226	psi-mi:“MI:0914”(association)	0.350
YWHAE	DEPDC5	psi-mi:“MI:0914”(association)	0.350
CCR1	UBA6	psi-mi:“MI:0914”(association)	0.350
SNAP29	SNAP23	psi-mi:“MI:0914”(association)	0.350
CREB3L2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
PPFIBP2	TBC1D4	psi-mi:“MI:0914”(association)	0.350
LAMP1	PIPSL	psi-mi:“MI:2364”(proximity)	0.270
	ARHGAP32	psi-mi:“MI:2364”(proximity)	0.270
NTRK1	C1orf226	psi-mi:“MI:2364”(proximity)	0.270
HSF4	PPFIBP2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (52): PPFIBP2 (Two-hybrid), PPFIBP2 (Two-hybrid), PPFIBP2 (Reconstituted Complex), PPFIA1 (Two-hybrid), PPFIA2 (Two-hybrid), PPFIBP2 (Biochemical Activity), PPFIBP2 (Two-hybrid), PPFIBP2 (Affinity Capture-RNA), PPFIBP2 (Affinity Capture-MS), PPFIBP2 (Affinity Capture-MS), PPFIBP2 (Affinity Capture-MS), PPFIBP2 (Two-hybrid), PPFIBP2 (Proximity Label-MS), PPFIBP2 (Proximity Label-MS), PPFIBP2 (Proximity Label-MS)

ESM2 similar proteins: A0A1L8GUX5, A0A1L8GXY6, A0A1W2P884, A2CE83, B8A5S6, E7F5E1, F7DP49, H2MTR9, O08970, O35711, O60296, P27628, P53564, P60853, Q0VF96, Q28GJ0, Q2KJD6, Q3UIJ9, Q4V7D3, Q5BIX7, Q5R923, Q5SXA9, Q5SZL2, Q5U2Y9, Q5U4W1, Q5ZLT3, Q6AW69, Q6DIS8, Q6DJR2, Q6NRW2, Q6NXJ0, Q6P402, Q6PCQ0, Q6PD31, Q7TQE6, Q80ST9, Q86W92, Q8BMK0, Q8C8U0, Q8CFC9

Diamond homologs: A9C3W3, O35711, O75145, O75334, O75335, P60469, Q13136, Q21049, Q5FWS6, Q674X7, Q69ZS8, Q86W92, Q8BSS9, Q8C8U0, Q8ND30, Q91Z79, Q91Z80, Q94071

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 31 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	182.7×	3e-11
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	161.2×	4e-11
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	161.2×	4e-11
Activation of BH3-only proteins	6	119.2×	2e-10
RHO GTPases activate PKNs	6	76.1×	3e-09
Intrinsic Pathway for Apoptosis	6	70.3×	5e-09
Translocation of SLC2A4 (GLUT4) to the plasma membrane	8	49.4×	9e-11
SARS-CoV-1-host interactions	6	42.2×	9e-08

GO biological processes:

GO term	Partners	Fold	FDR
intracellular protein localization	6	24.1×	4e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

172 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	130
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

4262 predictions. Top by Δscore:

Variant	Effect	Δscore
11:7565549:GCA:G	acceptor_loss	1.0000
11:7565551:A:AG	acceptor_gain	1.0000
11:7565551:AG:A	acceptor_gain	1.0000
11:7565552:G:GG	acceptor_gain	1.0000
11:7565552:GG:G	acceptor_gain	1.0000
11:7565552:GGC:G	acceptor_gain	1.0000
11:7565552:GGCA:G	acceptor_gain	1.0000
11:7565748:A:T	donor_gain	1.0000
11:7565763:GCTTG:G	donor_gain	1.0000
11:7565765:TTGGT:T	donor_loss	1.0000
11:7565767:GGTG:G	donor_loss	1.0000
11:7565768:G:GG	donor_gain	1.0000
11:7565768:G:T	donor_loss	1.0000
11:7565770:GAGTA:G	donor_loss	1.0000
11:7593130:A:AG	acceptor_gain	1.0000
11:7593131:G:GT	acceptor_gain	1.0000
11:7593131:GTC:G	acceptor_gain	1.0000
11:7593131:GTCC:G	acceptor_gain	1.0000
11:7593222:CAGG:C	donor_loss	1.0000
11:7593224:GGTG:G	donor_loss	1.0000
11:7593225:GT:G	donor_loss	1.0000
11:7610282:T:TA	acceptor_gain	1.0000
11:7610285:TTGCA:T	acceptor_loss	1.0000
11:7610287:GCAGG:G	acceptor_loss	1.0000
11:7610288:CA:C	acceptor_loss	1.0000
11:7610288:CAGG:C	acceptor_gain	1.0000
11:7610289:A:AG	acceptor_gain	1.0000
11:7610289:AG:A	acceptor_gain	1.0000
11:7610289:AGGA:A	acceptor_gain	1.0000
11:7610290:G:GT	acceptor_gain	1.0000

AlphaMissense

5738 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:7593214:T:C	L121P	0.999
11:7597570:T:C	L128P	0.999
11:7597612:T:C	L142P	0.999
11:7610295:T:C	L164P	0.999
11:7610304:G:C	R167P	0.999
11:7621014:T:C	L233P	0.999
11:7625793:T:C	L243P	0.999
11:7629478:T:C	L303P	0.999
11:7651732:G:C	R775P	0.999
11:7597570:T:A	L128H	0.998
11:7597666:T:C	L160P	0.998
11:7620960:T:C	L215P	0.998
11:7649577:A:C	S682R	0.998
11:7649579:C:A	S682R	0.998
11:7649579:C:G	S682R	0.998
11:7650894:T:A	W726R	0.998
11:7650894:T:C	W726R	0.998
11:7651723:T:A	L772H	0.998
11:7549513:T:C	L13P	0.997
11:7597579:A:C	Q131P	0.997
11:7597587:G:C	A134P	0.997
11:7597645:T:C	L153P	0.997
11:7625835:T:C	L257P	0.997
11:7628303:T:C	L282P	0.997
11:7649149:T:A	W638R	0.997
11:7649149:T:C	W638R	0.997
11:7650870:T:A	W718R	0.997
11:7650870:T:C	W718R	0.997
11:7650934:T:C	L739P	0.997
11:7651738:T:C	L777P	0.997

dbSNP variants (sampled 300 via entrez): RS1000013445 (11:7559084 T>C), RS1000017793 (11:7594599 T>C,G), RS1000030660 (11:7578183 A>G), RS1000072734 (11:7638722 C>G), RS1000090336 (11:7606855 T>C), RS1000095777 (11:7598277 C>T), RS1000116571 (11:7563227 G>A), RS1000214319 (11:7657636 C>G), RS1000232079 (11:7527074 C>T), RS1000239968 (11:7547167 C>T), RS1000265618 (11:7540256 G>C,T), RS1000284086 (11:7575889 G>A), RS1000307971 (11:7596149 T>C,G), RS1000334460 (11:7614765 T>G), RS1000367284 (11:7657735 C>A,T)

Disease associations

OMIM: gene MIM:603142 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST003148_2	Prostate cancer	4.000000e-08
GCST006075_11	Hair color	3.000000e-37
GCST006083_3	Prostate cancer (advanced)	1.000000e-07
GCST006085_46	Prostate cancer	7.000000e-09
GCST006988_49	Blond vs. brown/black hair color	1.000000e-42
GCST006989_21	Brown vs. black hair color	4.000000e-08
GCST007676_6	3-month functional outcome in ischaemic stroke (modified Rankin score)	4.000000e-06
GCST010302_37	Cutaneous melanoma or hair colour	2.000000e-33
GCST010725_20	Malaria	4.000000e-69
GCST010725_33	Malaria	2.000000e-67
GCST010725_51	Malaria	1.000000e-55

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0003924	hair color
EFO:0009603	stroke outcome severity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects cotreatment	4
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
Valproic Acid	increases expression, affects expression	3
Arsenic	affects methylation, decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Progesterone	affects response to substance, affects cotreatment, decreases expression	2
Tretinoin	increases expression	2
Cyclosporine	decreases expression	2
FR900359	affects phosphorylation	1
bisphenol A	affects cotreatment, decreases methylation	1
sodium arsenate	decreases expression, increases abundance	1
trichostatin A	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
3-nitrobenzanthrone	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
ICG 001	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Air Pollutants	decreases expression	1
Caffeine	decreases phosphorylation	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.